SAN FRANCISCO, April 20, 2021 /PRNewswire/ -- Kindred
Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company
focused on saving and improving the lives of pets, today
unveiled positive results in a new long-acting interleukin (IL)-31
antibody program (KIND-039) that integrates the company's novel
half-life extension technology. Results from the pharmacokinetic
study of the molecule demonstrate that the fully caninized,
high-affinity antibody has up to a three-fold longer half-life
compared to tirnovetmab. This extended half-life is expected to
allow for up to three-fold longer interval between dosing.
"One of the main unmet needs in the canine dermatitis market is
reduced dosing frequency and increased convenience. With these
exciting results, we believe our new long-acting IL-31 antibody
program has the potential to become a best-in-class therapeutic and
the treatment of choice in the large and growing dermatitis
market," said KindredBio's Chief Executive Officer, Richard
Chin, M.D. "We expect to initiate the pivotal study for this
molecule as early as the end of this year."
KindredBio's half-life extension technology is designed to
improve therapeutic performance in a multitude of ways. The reduced
dosing frequency and/or amount of dosing can lead to improved
patient convenience and compliance. The technology can also
significantly reduce the cost of goods and enhance profitability
and market positioning. In addition, higher drug concentration
using the same dose and dosing interval as the parent antibody can
result in extended and more uniform therapeutic exposure and
potentially improve efficacy and safety. KindredBio plans to
leverage this platform technology for long-lasting therapeutics to
develop to best-in-class products across multiple indications.
The new long-acting IL-31 program is expected to be
complementary to the company's tirnovetmab monoclonal antibody
program targeting IL-31, for which a pivotal study was initiated in
December, 2020. KindredBio's market research shows that longer
intervals between dosing is a key determinant of commercial
success, but given the large size of the market and the
heterogeneous nature of canine dermatitis, both products are
expected to be well-received by veterinarians and owners.
KindredBio first announced its half-life extension technology
for canine antibodies in January
2020.
About Kindred Biosciences
Kindred Biosciences is a biopharmaceutical company developing
innovative biologics focused on saving and improving the lives of
pets. Its mission is to bring to pets the same kinds of safe and
effective medicines that human family members enjoy. The Company's
strategy is to identify targets that have already demonstrated
safety and efficacy in humans and to develop therapeutics based on
these validated targets for dogs and cats. KindredBio has a deep
pipeline of novel biologics in development across many therapeutic
classes, alongside state-of-the-art biologics manufacturing
capabilities and a broad intellectual property portfolio.
For more information, visit: www.kindredbio.com
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, but not limited to,
statements regarding our expectations about the trials, regulatory
approval, manufacturing, distribution and commercialization of our
current and future product candidates, and statements regarding our
anticipated revenues, expenses, margins, profits and use of
cash.
These forward-looking statements are based on our current
expectations. These statements are not promises or guarantees, but
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results to be materially
different from any future results expressed or implied by the
forward-looking statements. These risks include, but are not
limited to, the following: our limited operating history and
expectations of losses for the foreseeable future; the absence of
significant revenue from our products and our product candidates
for the foreseeable future; the likelihood that our revenue will
vary from quarter to quarter; our potential inability to obtain any
necessary additional financing; our substantial dependence on the
success of our products and our lead product candidates which may
not be successfully commercialized even if they are approved for
marketing; the effect of competition; our potential inability to
obtain regulatory approval for our existing or future product
candidates; our dependence on third parties to conduct some of our
development activities; our dependence upon third-party
manufacturers for supplies related to our products and our
product candidates and the potential inability of these
manufacturers to deliver a sufficient amount of supplies on a
timely basis; the uncertain effect of the COVID-19 pandemic on our
business, results of operations and financial condition;
uncertainties regarding the outcomes of trials regarding our
product candidates; our potential failure to attract and retain
senior management and key scientific personnel; uncertainty about
our ability to enter into satisfactory agreements with third-party
licensees of our biologic products and uncertainty about the amount
of revenue that we will receive from such agreements; our
significant costs of operating as a public company; potential
cyber-attacks on our information technology systems or on our
third-party providers' information technology systems, which could
disrupt our operations; our potential inability to repay the
secured indebtedness that we have incurred from third-party
lenders, and the restrictions on our business activities that are
contained in our loan agreement with these lenders; the risk that
our 2020 strategic realignment and restructuring plans will result
in unanticipated costs or revenue shortfalls; uncertainty about the
amount of royalties that we will receive from the sale of Mirataz®
to Dechra Pharmaceuticals PLC; the risk that the revenue from our
delivery of services or products under any contract may be less
than we anticipate if the other party to the contract exercises its
right to terminate the contract prior to the completion of the
contract or if such party is unable or unwilling to satisfy its
payment obligations under the contract; our potential inability to
obtain and maintain patent protection and other intellectual
property protection for our products and our product candidates;
potential claims by third parties alleging our infringement of
their patents and other intellectual property rights; our potential
failure to comply with regulatory requirements, which are subject
to change on an ongoing basis; the potential volatility of our
stock price; and the significant control over our business by our
principal stockholders and management.
For a further description of these risks and other risks that we
face, please see the risk factors described in our filings with the
U.S. Securities and Exchange Commission (the SEC), including the
risk factors discussed under the caption "Risk Factors" in our
Annual Report on Form 10-K and any subsequent updates that may be
contained in our Quarterly Reports on Form 10-Q filed with the SEC.
As a result of the risks described above and in our filings with
the SEC, actual results may differ materially from those indicated
by the forward-looking statements made in this press release.
Forward-looking statements contained in this press release speak
only as of the date of this press release and we undertake no
obligation to update or revise these statements, except as may be
required by law.
The results stated in this press release have not been reviewed
by the Food and Drug Administration or the United States Department
of Agriculture Center for Veterinary Biologics, as applicable.
Contacts
For investor inquiries:
Katja Buhrer
Katja.buhrer@kindredbio.com
(917) 969-3438
View original content to download
multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-unveils-positive-results-from-its-long-acting-interleukin-31-antibody-pk-study-301273076.html
SOURCE Kindred Biosciences, Inc.